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canetti each carry a species-specific combination of spacers, allowing 
easy recognition of these species by spoligotyping. The function of 
the DR locus is unknown, but not essential for growth, as DR 
knockout mutants are viable. The existence of D R  loci in other 
bacterial species and their potentlal use in epidemiology will be 
discussed. 
Resistant bacteria-their evolution and 
pharmacodynamic response to 
antimicrobials 
Fitness costs of resistance and genetic 
compensation 
D. Anderson. Suedish Institute f o r  Infectious Diseases Control, Solna, 
Sweden 
The rate of development and stability of antibiotic resistance are 
determined by several factors, most of which have not been studied 
in any detail. For example, bacterial population sizes, mutation rates, 
antibiotic concentration heterogeneities in hosts, fitness costs of 
resistance, and the ability of bacteria to genetically compensate for 
such costs, are factors that will affect resistance dynamics. Of parti- 
cular interest are fitness costs and the amelioration of these costs by 
compensatory mutations. We have studied several types of chromo- 
somal resistances (due to target modifications) in several species of 
pathogenic bacteria. Results show that in most cases resistant bacteria 
are less fit, both in animal models and under laboratory conditions. 
However, this picture is con~plicated by the rapid appearance of 
compensatory mutations that restore fitness without loss of resistance. 
Thus, compensatory mutations could stabilize a resistant population 
and make resistance irreversible. 
Combination therapy as a tool to prevent 
emergence of resistance. What can be learnt 
from in vitro models? 
J.W. Mouton. Cunisius USlhelmina Hospital, Dept. ofMicrobiology, 
Ni jmepn,  The  Netherlands 
One of the possible strategies to prevent emergence of resistance is 
the use of combination therapy. In vitro pharmacokinetic models can 
be used to simulate various dosing regimens of the combinations, 
both to determine the optimal regimens to be used and to obtain 
insight into the selection process of resistant bacteria during those 
regimens. Most of the (few) studies performed show that, if resistance 
emerges during monotherapy, this can be prevented by the use of a 
combination. Experiments where Pseudomonus aenrginosa is treated 
with beta-lactani-aminoglycoside combinations indicate that this 
could be partly due to the supplementary kill by the aminoglycoside 
reducing the inoculum. The same conclusions can be drawn for the 
quinolone-beta-lactam combinations. By using inocula of two 
different strains with different MICs in various proportions, more 
insight is gained into this process. 
Progress in meningitis 
From gene to disease: the example of 
pneumococcal meningitis 
E. Tuomanen. S t l u d e  (ChiIdrenS Research) Hospital, Memphis, TN, 
USA 
The pneuinococcus adheres to activated blood-brain barrier 
endotheliaI cells via the PAF receptor, an interaction that enables 
endocytosis to occur. This route of entry to the central nervous 
system (CNS) involves a novel recyling route of trafficking and 
depends on the bacterial surface protein, CbpA. Expression of this 
protein is highly regulated. The bacteria transit cells of the cerebral 
microvasculature within a vacuole without intracellular multiplica- 
tion and enter the cerebrospinal fluid space. 
Death of glia and neurons is responsible for the sequelae of disease. 
Pneumolysin, a potent cytotoxin in the lung, is not required for this 
process in the CNS. Injury in the hippocampus I is prominent and 
involves caspase activation and classical apoptosis. This is particularly 
evident in the dentate gyrus, and neuronal and microglial cell death 
is attenuated in a rabbit meningitis model by inhibitors of caspase 
activation. The apoptosis requires participation of elements of the 
host inflammatory response. Other areas of the bran undergo a 
second type of apoptotic mechanism driven by the pneumococcus. 
Thus, preventing sequelae of pneumococcal meningitis may involve 
antibiotics and addition of apoptosis inhibitors in conjunction with 
down-modulation of inflammation. 
Prevention of infections in 
immunocompromised patients 
[s1061 Prevention of bacterial infections in cancer 
patients 
C. Viscoli. University of Genoa, Institutefor Cancer Research, Genoa, 
Italy 
Several procedures (from reverse isolation to total protective isolation 
with LAF rooms) have been proposed for the prevention of infection 
in cancer patients. However, most of these procedures are not cost- 
effective, so that standard precautions, including careful hand- 
washing and appropriate management of IV lines, remains the only 
effective method for preventing bacterial infections in this patient 
population. Isolation measures should rather be aimed at preventing 
the spread of transmissible diseases or multiresistant organisms within 
the hospital. Chemoprophylaxis with non-absorbable (total or 
selective intestinal decontamination) and absorbable antibiotics 
(selective decontamination+systemic prophylaxis) has also been 
studied and used extensively. Poor compliance, risk of recolonization 
with resistant organisms, development of resistance and lack of 
efficacy on pragmatic endpoints are common problems encountered 
with chemoprophylaxis. The most popular drugs that have been used 
(and are still used) are the Auoroquinolones. Indeed, these drugs were 
shown to provide a consistent reduction in the incidence of Gram- 
negative bacteremia, although with no effect on, or even an causing 
an increase in, Gram-positive bacteremia. Moreover, almost no study 
showed any effect on ‘strong’ endpoints, such as mortality, fever and 
need to use IV antibiotics. Finally, resistance to fluoroquinolones 
started to spread rapidly, especially amongst E. coli and staphylococci. 
Cancer patients are not all the same and high-risk patients might have 
benefited (and might still benefit) from prophylaxis. Unfortunately, 
